RE:RE:comments on the call prophet, you make a good point about the Dole partnership and the due diligence a company like that would do to explore all available options in this space. This partnership and the early excitement about where it could lead speaks to the fact that this technology is not being displaced by other competitng technologies or available options. But just as important is that Dole could prove to be a far more speedy to market partner. Aside from the many issues that have plagued the Nutradried segment, the other challenge has been the very long lead times of pharma, the army and many of the smaller niche players in actually generating large machine orders and eventually a healthy royalty stream. The US cannabis segment is also ripe for this "speed to market" trajectory. As states continue to legalize, the scale is now immense and this technology not only solves huge bottleneck issues but also offers validated data of an even more potent end product. The cannabis segment could potentially put the REV machine sales and royalty stream into a different gear..Let's hope the "domino effect" Brent mentioned could indeed come to fruition heading into FY 22.
As you or someone else mentioned, in the coming weeks or months we may get a couple of analysts upward guidance revisions.For now, I will happily continue to add more if given the opportunity in this .85 - .95 zone.